Programmed death-ligand 1 (PD-L1) immunohistochemistry is the main predictive tumor marker used to identify patients with advanced-stage NSCLC who are eligible for first-line treatment with immune checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.